Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: Implications for therapeutic drug monitoring of cyclosporin A

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 140-145

  Von Ahsen, Nicolas ^a   Helmhold, Marion ^a   Schütz, Ekkehard ^a   Eisenhauer, Thomas ^a   Armstrong, Victor W ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cyclosporin; Lipids; Therapeutic drug monitoring; Transplantation

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHELOMETRY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS; CYCLOSPORINE; DRUG MONITORING; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 0031453588     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00004     Document Type: Article

References (32)

1. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-95.
2. Wood AJ, Maurer G, Niederberger W, Beveridge T. Cyclosporine: pharmacokinetics, metabolism, and drug interactions. Transplant Proc 1983;15:2409-12.
3. Sgoutas D, Macmahon W, Love A, Jerkunica I. Interaction of cyclosporin A with human lipoproteins. J Pharm Pharmacol 1986;38:583-8.
4. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989;262:53-6.
5. Schorn TF, Kliem V, Bojanovski M, et al. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transplant Int 1991;4:92-5.
6. Raine AEG, Carter R, Mann JI, Morris PJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988;3:458-63.
7. Stamler JS, Vaughan DE, Rudd MA, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988;62:1268-72.
8. Luke DR, Beck JE, Vadiei K, Yousefpour M, LeMaistre CF, Yau JC. Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. J Clin Pharmacol 1990;30:163-9.
9. Lopez-Miranda J, Perez-Jimenez F, Torres A, et al. Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992;25:379-86.
10. Opelz G. Collaborative Transplant Study-10-year report. Transplant Proc 1992;24:2342-55.
11. Raine AEG. MacMahon SH, Selwood NH, Wing AJ, Brunner FP. Mortality from myocardial infarction inpatients on renal replacement therapy in the U.K. [Abstract]. Nephrol Dial Transplant 1991;6:902.
12. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989;48:37-43.
13. Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994;57:1479-83.
14. Kannel WB. Cholesterol and risk of coronary heart disease and mortality in men. Clin Chem 1988;34:853-9.
15. Stampfer MJ, Sacks FM, Salvini S, Willet WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-81.
16. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy. Transplantation 1990;50:987-92.
17. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984;33:521-6.
18. Holt DW and Johnston A. Cyclosporin A: methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit 1995;17:625-30.
19. McBride JH, Kim SS, Rodgerson DO, Reyes AF, Ota MK. Measurement of cyclosporine by liquid chromatography and three immunoassays in blood from liver, cardiac and renal transplant recipients. Clin Chem 1992;38:2300-6.
20. Dusci LJ, Hackett LP, Chiswell GM, Ilett KF. Comparison of cyclosporine measurement in whole blood by high-performance liquid chromatography, monoclonal fluorescence polarization immunoassay and monoclonal enzyme-multiplied immunoassay. Ther Drug Monit 1992;14:327-32.
21. LeGatt DF, Chooi M, Simpson AI, Yatscoff RW. EMIT cyclosporine assay: development of an application protocol for Technicon AXON system. Clin Biochem 1994;27:387-94.
22. Verrill HL, Girgis RE, Easterling RE, Malhi BS, Mueller WF. Distribution of cyclosporine in blood of a renal-transplant recipient with type V hyperlipoproteinemia. Clin Chem 1987; 33:423-8.
23. Nemunaitis J, Deeg HJ, Yee GC. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 1986;2:744-5.
24. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988; 34:461-4.
25. Lopez-Miranda J, Perez-Jimenez F, Gomez-Gerique J, et al. Effect of cyclosporin on plasma lipoprotein lipase activity in rats. Clin Biochem 1992;25:387-94.
26. Superko HR, Haskell WL, Di Ricco CD. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol 1990;66:1131-4.
27. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High-density lipoprotein 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987;80:341-7.
28. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449-53.
29. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1993;13:11-22.
30. Magill P, Rao SN, Miller NE, et al. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 1982; 12:113-20.
31. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17:642-54.
32. von Ahsen N, Armstrong VW, Helmhold M, Schütz E, Eisenhauer T, Oellerich M. Cyclosporin trough levels correlate with serum lipoproteins and apolipoproteins in renal transplant recipients [Abstract]. Ther Drug Monit 1995;17:430.